Qi, D., Liu, H., Sun, X., Luo, D., Zhu, M., Tao, T., . . . Xiao, J. (2021). Pristimerin Suppresses RANKL-Induced Osteoclastogenesis and Ameliorates Ovariectomy-Induced Bone Loss. Front Pharmacol.
Chicago ZitierstilQi, Dahu, et al. "Pristimerin Suppresses RANKL-Induced Osteoclastogenesis and Ameliorates Ovariectomy-Induced Bone Loss." Front Pharmacol 2021.
MLA ZitierstilQi, Dahu, et al. "Pristimerin Suppresses RANKL-Induced Osteoclastogenesis and Ameliorates Ovariectomy-Induced Bone Loss." Front Pharmacol 2021.
Achtung: Diese Zitate sind unter Umständen nicht zu 100% korrekt.